Aligos Therapeutics (ALGS) Common Equity (2019 - 2026)
Aligos Therapeutics' (ALGS) quarterly Common Equity came in at $31.8 million in Q1 2026, down 72.7% YoY from $116.4 million in Q1 2025, and down 40.63% on a QoQ basis from $53.5 million in Q4 2025.
Aligos Therapeutics (ALGS) Common Equity (2019 - 2026) Analysis & Trends
Aligos Therapeutics (ALGS) has 8 years of Common Equity data on file, last reported at $31.8 million in Q1 2026.
- Quarterly Common Equity fell 72.7% year-over-year to $31.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $31.8 million (down 72.7% YoY) and the FY2025 annual result came in at $53.5 million, up 284.81% from the prior year.
- Common Equity slipped to $31.8 million in Q1 2026, from $53.5 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $152.9 million in Q1 2022 to a low of -$29.0 million in Q4 2024.
- A 5-year average of $78.9 million and a median of $71.8 million in 2025 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2024 — Common Equity tumbled 131.47% — and 2025, when it surged 284.81%.
- Tracing ALGS's Common Equity over 5 years: stood at $103.9 million in 2022, then fell by 11.38% to $92.1 million in 2023, then plunged by 131.47% to -$29.0 million in 2024, then surged by 284.81% to $53.5 million in 2025, then slumped by 40.63% to $31.8 million in 2026.
- The last three Common Equity figures came in at $31.8 million (Q1 2026), $53.5 million (Q4 2025), and $71.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.57 Bn | 131.72 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.71 Bn | 78.72 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 65.44 Bn | 60.25 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.06 Bn | 54.93 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.89 Bn | 28.58 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.11 Bn | 9.72 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.59 Bn | 26.43 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 9.79 Bn |
| 10 | Aligos Therapeutics | 70.30 Mn | 39.86 Mn | - | 31.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 31.88 Mn |
| Mar 31, 2026 | 31.79 Mn |
| Dec 31, 2025 | 53.55 Mn |
| Sep 30, 2025 | 71.83 Mn |
| Jun 30, 2025 | 101.87 Mn |
| Mar 31, 2025 | 116.45 Mn |
| Dec 31, 2024 | -28.97 Mn |
| Sep 30, 2024 | 50.10 Mn |
| Jun 30, 2024 | 67.23 Mn |
| Mar 31, 2024 | 59.80 Mn |
| Dec 31, 2023 | 92.08 Mn |
| Sep 30, 2023 | 54.82 Mn |
| Jun 30, 2023 | 69.64 Mn |
| Mar 31, 2023 | 84.75 Mn |
| Dec 31, 2022 | 103.90 Mn |
| Sep 30, 2022 | 122.01 Mn |
| Jun 30, 2022 | 136.98 Mn |
| Mar 31, 2022 | 152.89 Mn |
| Dec 31, 2021 | 184.73 Mn |
| Sep 30, 2021 | 217.01 Mn |